{"title": "Estimating Spot Prevalence of COVID-19 from Daily Death Data in Italy", "doi": "10.1101/2020.03.17.20037697", "citation_id": "2020.03.17.20037697v1", "date": "2020-03-20", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.17.20037697", "abstract": "<p>COVID-19 like many infectious diseases has a variable severity. Due to limited testing capacity for new virus, the majority of infected showing mild or no symptoms it is likely current prevalence data is an underestimate. We present an estimate of the point prevalence of COVID-19 compared to the number of confirmed case in Italy based on the daily death rate and information about the incubation period, time from symptom onset to death and reported case fatality rate. Our model predicts that when the first 3 infected cases had been identified by Italian authorities there were already nearly 30 cases in Italy, and by the 24th of February 2020 only 0.5% cases had been detected and confirmed by Italian authorities. While official statistics had 132 confirmed case we believe a more accurate estimate would be closer to 26000. With a case-doubling period of about 2.5 days.</p>", "twitter_description": "COVID-19 like many infectious diseases has a variable severity. Due to limited testing capacity for new virus, the majority of infected showing mild or no symptoms it is likely current prevalence data is an underestimate. We present an estimate of the point prevalence of COVID-19 compared to the number of confirmed case in Italy based on the daily death rate and information about the incubation period, time from symptom onset to death and reported case fatality rate. Our model predicts that when the first 3 infected cases had been identified by Italian authorities there were already nearly 30 cases in Italy, and by the 24th of February 2020 only 0.5% cases had been detected and confirmed by Italian authorities. While official statistics had 132 confirmed case we believe a more accurate estimate would be closer to 26000. With a case-doubling period of about 2.5 days.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nno external funding was received\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nData not included in the article is available on request.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.17.20037697v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.17.20037697v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.17.20037697v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/20/2020.03.17.20037697.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.17.20037697v1", "access_rights": "restricted", "authors": ["Ali Raheem"]}